| Autor: |
Sgouros, J. Aravantinos, G. Koliou, G.-A. Pentheroudakis, G. Zagouri, F. Psyrri, A. Lampropoulou, D.I. Demiri, S. Pectasides, D. Razis, E. Fountzilas, G. Samantas, E. |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
Background/Aim: The efficacy of gemcitabinebased chemotherapy in locally advanced/metastatic biliary tract carcinoma is limited. The aim of this trial was to assess the activity of a novel gemcitabine-pazopanib combination in such patients. Patients and Methods: In this phase II, multicenter trial, patients with histologically/cytologically confirmed biliary tract carcinoma, previously untreated for advanced disease, received 1000 mg/m2 of gemcitabine on days 1 and 8 every 21 days and 800 mg of pazopanib once daily continuously for 8 cycles, followed by pazopanib maintenance. The primary endpoint was objective response rate (ORR). Results: A total of 29 patients (median age; 69 years) were enrolled between June 2013 and March 2018. The ORR was 13.8% in the intent-to-treat and 19.1% in the per protocol population. The median progression-free and overall survival were 6.3 and 10.4 months, respectively. Conclusion: The low response rate precludes further testing of the combination in patients with biliary tract carcinoma. © 2020 International Institute of Anticancer Research. All rights reserved. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
